HER-2/neu Signalling in Breast Cancer
Author Information
Author(s): MP DiGiovanna, D Carter, SD Flynn, DF Stern
Primary Institution: Yale University School of Medicine
Hypothesis
The variability in the prognostic ability of HER-2/neu overexpression may be due to active signalling in a subset of tumours.
Conclusion
HER-2/neu is phosphorylated and actively signalling in only a minority of invasive breast carcinomas that overexpress this receptor.
Supporting Evidence
- Overexpression of HER-2/neu was detected in 9% of 223 cases.
- Active signalling by HER-2/neu was detected in only 35% of the overexpressing cases.
- Phosphorylated HER-2/neu was associated with a lower rate of progesterone receptor positivity.
Takeaway
Some breast cancer tumors have a protein called HER-2/neu that can be active or inactive. Only a few of the tumors with high levels of this protein are actually active.
Methodology
The study involved immunohistochemical staining of 262 cases of invasive breast carcinomas, with 223 cases analyzed after excluding those without invasive carcinoma.
Limitations
The study's findings may be limited by the sensitivity of the antibodies used for detecting HER-2/neu.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website